Late-breaking clinical trials and science sessions have been announced for Transcatheter Cardiovascular Therapeutics 2025 conference.

The conference is set to take place from 25th to 28th October 2025 at the Moscone Center in San Francisco, CA. Access the full programme here.

Late-Breaking Clinical Trials: Session I, in Collaboration with The Lancet

Sunday 26th October, 11:00am – 12:28pm (PDT)

• One-Year Results of the SELUTION DeNovo Trial Comparing a Strategy of PCI with a Sirolimus-eluting Balloon and Provisional Stenting Versus Systematic DES Implantation to Treat DeNovo Coronary Lesions – Presented by Prof Christian Spaulding
• Sirolimus-Eluting Balloon Versus Repeat Drug-Eluting Stenting or Balloon Angioplasty for In-stent Restenosis – Presented by Dr Donald Cutlip
• Randomized Comparison of Intravascular Lithotripsy vs. Cutting Balloon Treatment in Calcified Coronary Artery Disease – The Short-CUT Trial – Presented by Dr Suzanne Baron
• A Randomized, Multicenter, Non-Inferiority Comparison of Intravascular Lithotripsy and Super-High-Pressure Non-Compliant Balloons for Treatment of Calcified and Refractory Coronary Lesions - The VICTORY Trial – Presented by Dr Matthias Bossard

Late-Breaking Clinical Science: Session I, in Collaboration with the European Heart Journal

Sunday 26th October, 14:00pm – 15:30pm (PDT)

• Randomized Controlled Trial of Mechanical Thrombectomy with Anticoagulation Versus Anticoagulation Alone for Acute Intermediate-High Risk Pulmonary Embolism: Results from STORM-PE – Presented by Dr Robert Lookstein
• Three-Year Outcomes of the LIFE-BTK Randomized Controlled Trial Evaluating the Esprit™ BTK Drug-Eluting Resorbable Scaffold for Treatment of Infrapopliteal Lesions – Presented by Dr Sahil Parikh
• Short-Term Anticoagulation Versus Dual Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure – Presented by Dr Josep Rodes-Cabau
• Evaluating Real-World Outcomes of the EVOQUE Valve in Early Commercial Experience from the STS/ACC TVT Registry – Presented by Dr Raj Makkar
• Lessons Learned from 800+ Patients Treated with Tricuspid TEER: Update from the TRILUMINATE Pivotal Trial – Presented by Dr Jonathan Schwartz

Late-Breaking Clinical Trials: Session II, in Collaboration with the New England Journal of Medicine

Monday 27th October, 11:00am – 12:28pm (PDT)

• Defining the Prevalence of Valvular Heart Disease in Older Americans: The PREVUE-VALVE Study – Presented by Dr David Cohen
• Long-Term Follow-up of the PARTNER 3 Low-Risk Randomized Trial: Seven-Year Clinical and Echocardiographic Outcomes – Presented by Dr Michael Mack
• Tendyne Transcatheter Mitral Valve System in Patients with Severe Mitral Annular Calcification: One-year Outcomes from the SUMMIT Severe MAC Cohort – Presented by Prof Paul Sorajja
• Percutaneous Transseptal Transcatheter Mitral Valve Replacement using a Dedicated Balloon Expandable Valve: 1 Year Outcomes from the ENCIRCLE Trial using the SAPIEN M3 – Presented by Dr David Daniels

Late-Breaking Clinical Science: Session II, in Collaboration with the Journal of the American College of Cardiology

Monday 27th October, 14:00pm – 15:30pm (PDT)

• Long Term Clinical Outcomes in Patients Treated with the Bioadaptor Compared with a Contemporary Drug Eluting Stent: The INFINITY-SWEDEHEART Randomized Trial – Presented by Prof David Erlinge
• Comparison of Drug-Coated Versus Conventional Balloons for Treatment of Side Branches of Bifurcation Lesions: The OCVC-BIF Study – Presented by Dr Takayuki Ishihara
• Sirolimus-Eluting Iron Bioresorbable Scaffold in Coronary Artery Disease: Two-Year Results of IRONMAN-II Randomized Controlled Trial – Presented by Dr Lei Song
• Drug-Coated Balloon Angioplasty with Rescue Stenting Versus Intended Stenting for the Treatment of DeNovo Coronary Artery Lesions: 3-Year Clinical Outcomes of the REC-CAGEFREE I Trial – Presented by Dr Chao Gao
• Percutaneous Coronary Angioplasty Versus Coronary Artery Bypass Grafting in the Treatment of Unprotected Left Main Stenosis: 10-year Mortality Outcomes from the Randomized NOBLE Trial – Presented by Dr Evald Christiansen

Late-Breaking Clinical Trials: Session III, in Collaboration with the Journal of the American Medical Association

Tuesday 28th October, 11:00am – 12:30pm (PDT)

• Percutaneous Coronary Intervention of Native Coronary Artery versus Saphenous Vein Graft in Patients with Prior Coronary Artery Bypass Graft Surgery (PROCTOR): A Multicenter, Open-label, Randomized Trial – Presented by Dr Ruben de Winter
• Effects of Intracoronary Low-Dose Recombinant Tissue Plasminogen Activator as an Ajunct to Primary PCI in Patients with STEMI and Large Thrombus Burden: A Randomized, Double-Blind, Placebo-Controlled Trial – Presented by Dr Shamir Mehta
• Immediate Instantaneous Wave-Free Ratio Guided Versus Deferred Cardiac Magnetic Resonance Imaging Guided Revascularization of Non-Culprit Lesions in Patients with Acute ST-Elevation Myocardial Infarction: A Randomized Superiority Trial – Presented by Prof Robin Nijveldt
• Stratified Treatment of Myocardial Infarction with Non-Obstructive Coronary Arteries: The PROMISE Trial – Presented by Dr Rocco Antonio Montone
• Supraflex Cruz versus Xience in Patients with Diabetes and Multivessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: Results from the TUXEDO-2 Randomized Trial – Presented by Dr Upendra Kaul

Late-Breaking Clinical Science: Session III, in Collaboration with Circulation

Tuesday 28th October, 14:00pm – 15:30pm (PDT)

• iFR Versus Angiography-Guided CABG: 3-Year Results of the iCABG Randomized Trial – Presented by Dr Rasa Ordiene
• Randomized Comparison of the Supraflex CruzTM vs. SYNERGYTM Drug-Eluting Stents: The Multivessel TALENT Randomized Trial – Presented by Dr Patrick Serruys
• A Prospective, Randomized Clinical Trial of Hemodynamic Support with a Novel Developed pVAD Versus IABP in Patients Undergoing High-Risk Percutaneous Coronary Intervention – Presented by Mr Rui Wang
• AI-Enabled ECG Interpretation in STEMI: Findings from a Multicenter U.S. Registry – Presented by Dr Timothy Henry
• The Effectiveness and Safety of a Planned Investment Procedure in High-Risk Chronic Total Occlusions - The INVEST CTO Single Arm Study – Presented by Dr Anja Oksnes

References

TCT Conference. Programme Guide. 2025. https://www.tctconference.com/program-guide (accessed 11 September 2025).